Unlock instant, AI-driven research and patent intelligence for your innovation.

Structured molecular vectors for anti-inflammatory compounds and uses thereof

A technology of compounds and hydrates, applied in phosphorus organic compounds, anti-inflammatory agents, compounds of Group 5/15 elements of the periodic table, etc.

Pending Publication Date: 2021-11-19
UNIV CLAUDE BERNARD LYON 1 +3
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although glycerophospholipid-based carriers have better brain targeting than ethyl- and triglyceride-based versions, they have monovalent carriers that are fatty acids (eg, only docosahexaenoic acid) and can only be delivered short-term the inconvenience

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Structured molecular vectors for anti-inflammatory compounds and uses thereof
  • Structured molecular vectors for anti-inflammatory compounds and uses thereof
  • Structured molecular vectors for anti-inflammatory compounds and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment A

[0382] Example A: Synthesis

[0383] Synthesis of I.1.SSL-X compound (n=0)

[0384] 1. bio-based approach

[0385] The synthesis of SSL-X was performed using ceramide aminoethylphosphonate (CAEP), which is relatively abundant in certain marine organisms, especially bivalve molluscs such as the blue mussel (Mytilus galloprovincialis). For this purpose, total lipids were extracted and purified according to the Folch method (Folch J., Lees M. and Stanley G.H.S., (1957), A simple method for the isolation and purification of total lipids from animal tissues of total lipids from animal tissues), J. Biol. Chem. 226, 497-509). The lipids are then saponified. After purification of the unsaponifiable lipid fraction, the CAEP was deacylated using strong basic or acidic hydrolysis. The deacylated CAEP was then purified and quantified. SSL-X1, SSL-X2 and SSL-X3 were then synthesized by N-acylation. figure 1 The synthesis procedure is shown.

[0386] The detailed procedure for SS...

Embodiment B

[0429] Example B: Biological Results

Embodiment B-1

[0430] Example B-1: Metabolic fate of SSL in the digestive tract

[0431] Materials and methods

[0432] animal

[0433] Rats used in our experiments were Sprague Dawley male rats (Charles River, Saint Germain sur L'Arbresle, France), ~200 g upon receipt at an approved animal facility, maintained at a temperature of 21 °C and diurnal conditions ( The light period is from 06:00 to 18:00). The rats were divided into groups of 5 individuals in each cage, and water and food were taken ad libitum. All animal testing procedures comply with European Directive 86 / 609 transposed into French law by Decree 87 / 848. Every effort is made to minimize animal suffering and stress and to reduce the number of animals used. Animals were used two weeks after arrival at the animal facility.

[0434] Administering SSL to Animals

[0435]Research on the fate of SSL in the digestive tract was performed on SSL-X1. For this, an aliquot of SSL-X1 corresponding to 227 μg of lipid phospholip...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
electrical resistanceaaaaaaaaaa
Login to View More

Abstract

The present invention relates to structured molecular vectors of formula (I), compounds of formula (II) and pharmaceutical compositions comprising such compounds. The invention also relates to such pharmaceutical compositions for use for preventing and / or treating a disease chosen among an inflammatory disease or a disease associated with a cognitive disorder. The invention further relates to such pharmaceutical compositions for use for preventing cognitive decline or restoring cognitive functions altered in brain injuries and / or in traumatic brain injuries and / or in a neuroinflammatory disease, and / or in a neurodegenerative disease.

Description

technical field [0001] The present invention relates to carrier compounds of different biologically active compounds, in particular having strong anti-inflammatory properties, capable of restoring cognition and preventing cognitive decline and / or reducing the severity and frequency of epileptic seizures. The invention also relates to the use of such compounds for the treatment of disorders of neurological, psychiatric and peripheral type, in particular disorders of inflammatory origin. The present invention also relates to ethanolamine, ethanolamine-phosphonate and ethanolamine-phosphate fatty acid derivatives and their use in therapeutic and non-therapeutic applications alike. Background technique [0002] Compounds of the omega-3 fatty acid type represent an important market in the health sector, considering their numerous advantages. In fact, these compounds are active in the prevention of a large number of diseases in which inflammation is a common feature. Inflammatio...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/661A61K31/662A61K31/685A61K31/688A61P1/00A61P25/28A61P29/00A61K31/131C07F9/38C07F9/40A23L33/12
CPCA61K31/131C07F9/3817C07F9/4009A23L33/12A61K31/661A61K31/662A61K31/685A61K31/688A61P1/00A61P25/28A61P29/00A23L29/04C07F9/09A61P25/08
Inventor 雅克·博登内克阿莫尔·贝尔梅格内伊赛琳娜·博登内克劳伦特·贝津比阿特丽斯·乔治维克多·布洛特
Owner UNIV CLAUDE BERNARD LYON 1